What is Enlivex Therapeutics Ltd. (ENLV.TA)?

Enlivex Therapeutics Ltd. (ENLV.TA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Enlivex Therapeutics Ltd. (ENLV.TA)

Stock analysis · TLV · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.68

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Enlivex Therapeutics Ltd. (ENLV.TA) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 25, 2026

EPS $-0.45 vs est. $-0.27

Missed by $0.18

Proprietary Signals

Signal snapshot temporarily unavailable.

About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in immunotherapy through macrophage reprogramming. The company's primary therapeutic candidate, Allocetra, is a cell-based treatment currently in a Phase II clinical trial for organ dysfunction and failure linked to sepsis. Allocetra is also being investigated in preclinical studies for its application against solid tumors. Furthermore, Enlivex has partnered with BeiGene to evaluate Allocetra's safety and efficacy when administered alongside tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for advanced solid tumor patients. The company's headquarters are located in Ness Ziona, Israel.